EX-99.1 2 c00185exv99w1.htm EXHIBIT 99.1 Exhibit 99.1
Exhibit 99.1
Contact:
McDavid Stilwell
GTx, Inc.
Director, Corporate Communications & Financial Analysis
901-523-9700
GTX, INC. REPORTS FIRST QUARTER 2010 CORPORATE RESULTS
MEMPHIS — May 4, 2010 — GTx, Inc. (Nasdaq: GTXI) today reported financial results for the first quarter of 2010. The net income for the first quarter ended March 31, 2010 was $44.3 million compared with a net loss of $11.3 million for the same period in 2009. Net income for the current period included the recognition of approximately $54.9 million in collaboration revenue due to the termination of our license and collaboration agreement with Merck & Co., Inc. in March 2010.
“GTx made good progress in the first quarter across all clinical programs,” said Mitchell S. Steiner, CEO of GTx. “We secured financing for the second toremifene 80 mg Phase III clinical trial through the expansion of our partnership with Ipsen. The last patient completed the toremifene 20 mg Phase III high grade PIN clinical trial, and we are on track to receive data from the study this summer. Reacquiring full rights to our SARM program will allow GTx to move ostarine forward into late stage studies for cancer cachexia and to explore new partnership opportunities. Finally, we initiated a Phase II clinical trial for GTx-758, a novel oral LH inhibitor for first line treatment of advanced prostate cancer, and we expect results later this summer.”
Clinical Development and Product Candidate Pipeline Updates
  •   Toremifene 80 mg to reduce fractures in men with prostate cancer on androgen deprivation therapy (ADT): GTx has submitted to the United States Food and Drug Administration (FDA) a proposed protocol for the Phase III TREAT 2 (Toremifene for Reduction of fractures and other Estrogen deficiency side effects in men on Androgen deprivation Therapy) clinical trial. GTx expects to initiate the TREAT 2 clinical trial this year after receiving feedback from FDA.
 
  •   Toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN): The last patient completed the toremifene 20 mg Phase III high grade PIN clinical trial in February. GTx expects to receive data from the study and to announce results of the trial in the summer of 2010.

 

 

 

  •   Ostarine™ and other selective androgen receptor modulators (SARMs): GTx is planning to request a meeting with FDA in May to discuss the late stage clinical development of ostarine for the treatment of cancer cachexia.
 
  •   GTx-758, an oral luteinizing hormone (LH) inhibitor for the first line treatment of advanced prostate cancer: GTx initiated a Phase II clinical trial evaluating GTx-758 in February and anticipates receiving results from the study in the third quarter.
First quarter 2010 financial highlights
The net income for the quarter ended March 31, 2010 was $44.3 million compared with a net loss of $11.3 million for the same period in 2009.
Revenue for the first quarter of 2010 was $56.6 million compared to $3.6 million for the same period in 2009. Revenues included net sales of FARESTON® (toremifene citrate) 60 mg, marketed for the treatment of metastatic breast cancer in postmenopausal women and collaboration revenue from our collaborations with Ipsen Biopharm Limited and Merck & Co., Inc. Net sales of FARESTON® were $799,000 and $759,000 for the three months ended March 31, 2010 and 2009, respectively. Collaboration revenue was $55.8 million and $2.9 million for the first quarter of 2010 and 2009, respectively. Collaboration revenue for the first quarter of 2010 included the recognition of approximately $54.9 million as a result of the termination of our license and collaboration agreement with Merck in March 2010. Additionally, collaboration revenue in the current quarter included approximately $922,000 from the amortization of deferred revenue from Ipsen. Collaboration revenue for the first quarter of 2009 consisted of approximately $1.5 million and approximately $1.4 million from the amortization of deferred revenue from Ipsen and Merck, respectively.
For the three months ended March 31, 2010 and 2009, research and development expenses were $7.7 million and $8.3 million, respectively. General and administrative expenses decreased during the three months ended March 31, 2010 to $4.5 million from $6.5 million for the three months ended March 31, 2009.
At March 31, 2010 GTx had cash, cash equivalents and short-term investments of $38.7 million.
Conference Call
There will be a conference call today at 9 a.m. Eastern Time to discuss GTx’s first quarter financial results and to provide a company update. To listen to the conference call, please dial:

 

 

 

  •   866-770-7129
from the United States and Canada or
  •   617-213-8067 (International)
The access code for the call is 47619023.
A playback of the call will be available beginning today at 12:00 p.m. Eastern Time through May 18, and may be accessed by dialing:
  •   888-286-8010 from the United States and Canada or
 
  •   617-801-6888 (International)
 
      The reservation number for the replay is 43873249.
Additionally, you may access the live and subsequently archived webcast of the conference call from the Investor Relations section of the company’s website at http://www.gtxinc.com.
About GTx
GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways for the treatment and prevention of cancer, the treatment of side effects of anticancer therapy, cancer supportive care, and other serious medical conditions.
Forward-Looking Information is Subject to Risk and Uncertainty
This press release contains forward-looking statements based upon GTx’s current expectations. Forward-looking statements include, but are not limited to, statements relating to GTx’s plans to continue to pursue the development of and marketing approval for, and the potential commercialization of, toremifene 80 mg, and the continued development and potential commercialization of GTx’s other product candidates. Forward-looking statements involve risks and uncertainties. GTx’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks (i) that GTx and its collaboration partner will not be able to commercialize their product candidates if clinical trials do not demonstrate safety and efficacy in humans, including in any additional clinical trials that GTx may conduct for toremifene 80 mg to reduce fractures in men with prostate cancer on ADT; (ii) that GTx may not be able to obtain required regulatory approvals to commercialize its product candidates, including toremifene 80 mg to reduce fractures in men with prostate cancer on ADT or toremifene 20 mg for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, in a timely manner or at all; (iii) that clinical trials being conducted or planned to be conducted by GTx and its collaboration partner may not be initiated or completed on schedule, or at all, or may otherwise be suspended or terminated; (iv) related to GTx’s dependence on its collaboration partner for product candidate development and commercialization efforts; (v) related to GTx’s reliance on third parties to manufacture its product candidates and to conduct its clinical trials; and (vi) that GTx could utilize its available cash resources sooner than it currently expects and may be unable to raise capital when needed, which would force GTx to

 

 

 

delay, reduce or eliminate its product candidate development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx’s annual report on Form 10-K filed with the SEC on March 15, 2010 contains under the heading, “Risk Factors,” a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

 

 

 

GTx, Inc.
CONDENSED BALANCE SHEETS
(in thousands, except share data)
                 
    March 31,     December 31,  
    2010     2009  
    (unaudited)      
ASSETS
                
Current assets:
                
Cash and cash equivalents
   $ 29,581     $ 40,219  
Short-term investments
     9,109       8,825  
Accounts receivable, net
     519       406  
Inventory
     66       116  
Prepaid expenses and other current assets
     6,899       1,109  
 
            
Total current assets
     46,174       50,675  
Property and equipment, net
     3,021       3,291  
Intangible and other assets, net
     3,670       3,755  
 
            
Total assets
   $ 52,865     $ 57,721  
 
            
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
                
Current liabilities:
                
Accounts payable
   $ 826     $ 1,268  
Accrued expenses
     5,055       4,730  
Deferred revenue — current portion
     3,691       9,954  
 
            
Total current liabilities
     9,572       15,952  
Deferred revenue, less current portion
     5,383       49,898  
Other long term liabilities
     607       621  
Commitments and contingencies
                
Stockholders’ equity (deficit):
                
Common stock, $0.001 par value: 60,000,000 shares authorized; 36,420,901 shares issued and outstanding at March 31, 2010 and December 31, 2009
     36       36  
Additional paid-in capital
     361,102       359,388  
Accumulated deficit
     (323,835 )     (368,174 )
 
            
Total stockholders’ equity (deficit)
     37,303       (8,750 )
 
            
Total liabilities and stockholders’ equity (deficit)
   $ 52,865     $ 57,721  
 
            

 

 

 

GTx, Inc.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
                 
    Three Months Ended  
    March 31,  
    2010     2009  
Revenues:
                
Product sales, net
   $ 799     $ 759  
Collaboration revenue
     55,778       2,872  
 
            
Total revenues
     56,577       3,631  
Costs and expenses:
                
Cost of product sales
     151       348  
Research and development expenses
     7,650       8,312  
General and administrative expenses
     4,509       6,511  
 
            
Total costs and expenses
     12,310       15,171  
 
            
Income (loss) from operations
     44,267       (11,540 )
Other income, net
     72       45  
 
            
Income (loss) before income taxes
     44,339       (11,495 )
Income tax benefit
     —        194  
 
            
Net income (loss)
   $ 44,339     $ (11,301 )
 
            
 
                
Net income (loss) per share:
                
Basic and diluted
   $ 1.22     $ (0.31 )
 
            
 
                
Weighted average shares used in computing net income (loss) per share:
                
Basic and diluted
     36,420,901       36,404,608